

Karol Kaltenbach

PhD Clinical Associate Professor of Paediatrics, Psychiatry and Human Behavior; Director, Maternal Addiction Treatment Education and Research; Department of Paediatrics Jefferson Medical College Thomas Jefferson University, Philadelphia).

Dr. Karol Kaltenbach is the Director of Maternal Addiction Treatment, Education and Research (**MATER**), a division of the Department of Pediatrics, Jefferson Medical College. **MATER** includes “Family Centre”, a comprehensive intensive outpatient treatment program for pregnant and parenting opioid dependent women; “My Sister’s Place”, a long-term residential treatment program for women and children; and a research component. Nationally and internationally, Family Centre has provided the prototype both for the management of opioid dependency during pregnancy and the treatment of neonatal abstinence.

Dr Kaltenbach holds faculty appointments as Clinical Associate Professor of Pediatrics and as Clinical Associate Professor of Psychiatry and Human Behavior at the Jefferson Medical College of Thomas Jefferson University. She is a member of the Society for Research in Child Development, and the College on Problems of Drug Dependence. Dr Kaltenbach has been the Principle Investigator of grants from the National Institute on Drug Abuse (NIDA) and the Centre for Substance Abuse Treatment. She is currently a Principle Investigator of the NIDA MOTHER clinical trial comparing the use of methadone and buprenorphine in pregnant opioid dependent women and is a co-investigator of a NIDA funded study investigating the use of buprenorphine in the treatment of neonatal abstinence syndrome (NAS).

Dr. Kaltenbach has published numerous articles and book chapters on the management of opioid dependence during pregnancy and on NAS; gender specific treatment for pregnant and parenting substance abusing women; and the effect of prenatal drug exposure on the perinatal and developmental outcome of children. She has lectured throughout the world and has participated in the development of national guidelines for the management of opioid dependent pregnant women and their neonates in Australia and Norway.